Ian A Wilson

This inventor holds 22 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Vaccine Development. Top assignees: Scripps Research Institute, International Aids Vaccine Initiative, Texas A&M University System. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ian A Wilson. Retrieved from https://idiyas.com/inventor/ian-a-wilson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 11)

% Patents Active = 90.9

CIPO Patents = 4

EPO Patents = 5 (Patent Applications = 16)

Average Co-Inventor Count = 4.4

ph-index = 3

Forward Citations = 79(Granted Patents)

Company Filing History:

21 out of 1,208

Scripps Research Institute

patents

2 out of 72

International Aids Vaccine Initiative

patents

2 out of 1,330

Texas A&M University System

National Center for Aids/std Control and Prevention, Chinese Center for Disease Control and Prevention

patents

6. 1 out of 1,383

Washington University

patents

where one patent can have more than one assignee

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

HIV Antibodies

Vaccine Design

Ebolavirus

Coronovirus Immunogens

Influenza Antigens

Broadly Neutralizing Antibodies

Nucleic Acids

Engineered Immunogens

Hemagglutinin Trimers

Erythropoietin Mimetics

GP140 Immunogens

HCV E2 Immunogens

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715907 - RAPID ELICITATION OF BROADLY NEUTRALIZING BOVINE ANTIBODIES TO HIV ENV (2026-08-25),

2. 12617843 - HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION (2026-05-05),

3. 12509503 - PAN-NEURAMINIDASE INHIBITING ANTIBODIES (2025-12-30),

4. 12448416 - Stabilized coronavirus spike (s) protein immunogens and related vaccines (2025-10-21),

5. 12109261 - Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens (2024-10-08),

6. 11872277 - Compositions and methods related to ebolavirus vaccines (2024-01-16),

7. 11845777 - Stabilized coronavirus spike (S) protein immunogens and related vaccines (2023-12-19),

8. 11795211 - Rapid elicitation of broadly neutralizing antibodies to HIV Env (2023-10-24),

9. 11767347 - HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations (2023-09-26),

10. 11305004 - Compositions and methods related to ebolavirus vaccines (2022-04-19),

11. 11236134 - Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations (2022-02-01),

12. 11008368 - Engineered HCV E2 immunogens and related vaccine compositions (2021-05-18),

13. 10934345 - Broadly neutralizing antibodies against HIV-1 and use thereof (2021-03-02),

14. 10906944 - Stabilized coronavirus spike (S) protein immunogens and related vaccines (2021-02-02),

15. 10647748 - HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations (2020-05-12),

Title: Innovative Contributions of Ian A. Wilson in Vaccine Development

Introduction

Ian A. Wilson, an esteemed inventor based in La Jolla, CA, is known for his groundbreaking work in the field of vaccine development. With 18 patents to his name, he has significantly advanced the understanding and treatment of viral infections, particularly influenza and Ebolavirus.

Latest Patents

Wilson’s latest patents are a testament to his innovative spirit. One of his notable inventions is the "Stabilized Hemagglutinin (HA) Trimers as Influenza Vaccine Antigens." This invention provides novel engineered influenza hemagglutinin proteins, related polynucleotide sequences, and vaccine compositions that include nanoparticle compositions. The engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention further offers methods for using such vaccine compositions in various therapeutic applications, including preventing or treating influenza viral infections.

Another significant contribution is his work on "Compositions and Methods Related to Ebolavirus Vaccines." This patent encompasses novel engineered Ebolavirus GP proteins and polypeptides, alongside scaffolded vaccine compositions displaying these engineered proteins. It also includes polynucleotides encoding the engineered proteins, which can be utilized in various therapeutic applications for Ebolavirus infections.

Career Highlights

Throughout his career, Ian A. Wilson has made impactful contributions to vaccine research and development. He has held significant positions at prestigious organizations such as The Scripps Research Institute and the International Aids Vaccine Initiative. His work in these institutions has cemented his reputation as a pioneer in the field.

Collaborations

In his journey, Ian A. Wilson has collaborated with talented professionals, including Linling He and Jiang Zhu. These collaborations have allowed for the exchange of ideas and innovations that further advance vaccine research and development.

Conclusion

Ian A. Wilson's contributions to vaccine technology, highlighted by his numerous patents, showcase his dedication to combating viral infections. His innovative approaches and collaborations continue to inspire progress in the medical and scientific communities, paving the way for safer and more effective vaccines.

Profile summary based on public USPTO records.